Selegiline and mortality in Parkinson's disease

Annals of Neurology

Volumn 40, Issue 6, 1996, Pages 841-845

  Olanow, C W ^a   Fahn, S ^b   Langston, J W ^c   Godbold, J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Parkinson Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; SELEGILINE;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG MIXTURE; HUMAN; META ANALYSIS; MORTALITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; UNITED KINGDOM;

CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS; SELEGILINE;

EID: 0030497679     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400605     Document Type: Review

References (37)

1. Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the antiakinetic effect after 1-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36:303-326
2. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of 1-deprenyl to Madopar treatment of Parkinson's disease: a long-term study. J Neural Transm 1985;64:113-127
3. Knoll J. Extension of life span of rats by long-term (-)deprenyl treatment. Mt Sinai J Med 1988;55:67-74
4. Milgram NW, Racine RJ, Nellis P, et al. Maintenance of 1-deprenyl prolongs life in aged male rats. Life Sci 1990;47:415-420
5. Kitani K, Kanai S, Sato Y, et al. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci 1993;52:281-288
6. Langsten JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984; 225:1480-1482
7. Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 1984;311:467-469
8. Cohen G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1985; 106:209-210
9. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 1985;45:1951-1953
10. Finnegan KT, Skratt JJ, Irwin I, et al. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 1990;184:119-126
11. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-677
12. + in vivo. Eur J Pharmacol 1993; 243:241-247
13. Ansari KS, Yu PH, Kruck TPA, Tatton WG. Rescue of axotomized immature rat facial motoneurons by L-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053
14. Salo PT, Tatton WG. L-Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992;31:394-400
15. Tatton WG, Ju WYL, Holland DP, et al. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575
16. Tatton WG, Ju WYH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promises for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youdim MHB, eds. Neurodegeneration and neuroprotection. London: Academic Press, 1996:202-220
17. Olanow CW, Hauser RA, Gauger L, et al. A longitudinal double blind controlled study of the affect of deprenyl and levodopa on the progression of the signs and symptoms of Parkinson's disease. Ann Neurol 1995;38:771-777
18. Lees AJ, on behalf of the Parkinsons Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995;311:1602-1606
19. Calne DB. Selegiline in Parkinson's disease. Br Med J 1995; 311:1583-1584
20. Olanow CW, Godbold J, Koller WC. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Br Med J 1996;312:702-703
21. Maki-Ikola O, Kilkku O, Heinonen E. Other studies have not shown increased mortality. Br Med J 1996;312:702 (Abstract)
22. Di Rocco A, Culliton DA, Yahr MD. Comparative mortality and longevity in parkinsonian patients treated with L-dopa alone or L-dopa and selegiline. Mov Disord 1996;11:189 (Abstract)
23. Ben Shlomo Y, Marmot MC. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;38:293-299
24. Jellinger KA. Neurodegenerative disorders with extrapyramidal features - a neuropathological review. J Neural Transm 1995; 46:33-56
25. Parkinson Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993;307: 469-472
26. Haybittle JL. Repeated assessments of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793-797
27. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-199
28. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
29. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential trials. Controlled Clin Trials 1984;5:348-361
30. Tsiatis AA, Rosner GL, Mehta CR. Exact confidence intervals following a group sequential test. Biometrics 1984;40:797-803
31. Coronary Drug Project Research Group. Practical aspects of decision making in clinical trials: the coronary drug project as a case study. Controlled Clin Trials 1981;1:363-376
32. Cox DR. Regression models and life tables. JRSS(B) 1972;34: 187-220
33. Brannan T, Prikhojan A, Martinez-Tica J, Yahr MD. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-dopa and dopamine metabolism. J Neural Transm 1995;10:79-89
34. Wachtel SR, Abercrombie ED. L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 1994;63:108-117
35. Myllyla VV, Heinonen E, Vuorinen JA, et al. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta Neurol Scand 1995;91:177-182
36. Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: Prado study discontinued. Eur J Clin Pharmacol 1992; 43:357-363
37. Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc 1996;71:659-670